Rocket Pharmaceuticals, Inc. (RCKT) 

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Show less

Over the last 12 months, insiders at Rocket Pharmaceuticals, Inc. have bought $0 and sold $12.85M worth of Rocket Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Rocket Pharmaceuticals, Inc. have bought $14.54M and sold $19.28M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,355,932 shares for transaction amount of $20M was made by WONG RODERICK (director) on 2022‑10‑06.